natur
target
liposom
cell
reticuloendotheli
system
exploit
examin
whether
select
deliveri
antivir
immunomodulatori
agent
could
benefici
treatment
viral
diseas
review
discuss
potenti
use
liposom
treatment
viru
diseas
target
liposomeencapsul
immunomodul
macrophag
order
render
cell
cytolyt
virusinfect
cell
target
liposomeencapsul
antivir
drug
macrophag
achiev
direct
suppress
viru
replic
within
cell
although
viral
diseas
man
anim
major
caus
morbid
mortal
henc
econom
loss
earli
hope
antivir
panacea
fulfil
lack
success
treatment
viral
diseas
due
part
fact
viral
replic
intim
associ
host
cell
biosynthet
machineri
recent
discoveri
molecular
biolog
viru
replic
identifi
sever
viruscod
function
potenti
target
select
inhibit
antivir
agent
moreov
advanc
rapid
viral
diagnosi
allow
identif
caus
agent
earli
cours
diseas
viral
replic
occur
potenti
treatment
viral
diseas
never
greater
one
challeng
develop
effect
viral
therapeut
deliv
antivir
agent
site
viru
replic
challeng
uniqu
viral
diseas
inde
drug
target
becom
focu
extens
studi
treatment
cancer
fungal
bacteri
parasit
diseas
recent
substanti
effort
direct
evalu
synthet
phospholipid
vesicl
ie
liposom
drug
deliveri
system
could
target
therapeut
agent
organ
cellular
site
diseas
capac
liposom
encapsul
wide
varieti
hydrophil
lipophil
biolog
activ
compound
make
extrem
attract
potenti
vehicl
drug
deliveri
vivo
liposom
howev
like
particul
matter
clear
circul
phagocyt
cell
reticuloendotheli
system
re
limit
transcapillari
transport
liposom
follow
intraven
inject
occur
liver
open
sinusoid
capillari
occur
continu
capillari
lung
howev
liposom
lung
capillari
engulf
circul
blood
monocyt
subsequ
migrat
aiveoli
becom
alveolar
macrophag
although
biolog
realiti
present
major
drawback
use
liposom
deliv
drug
cell
phagocyt
cell
permit
natur
target
drug
cell
re
studi
fidler
post
colleagu
taken
advantag
select
deliveri
liposom
cell
monocytemacrophag
seri
demonstr
deliveri
encapsul
immunomodul
cytoplasm
macrophag
render
cell
highli
tumoricid
vitro
vivo
moreov
repeat
intraven
inject
liposom
contain
immunomodul
respons
erad
spontan
melanoma
metastas
lung
lymph
node
syngen
mice
recent
editori
schroit
et
al
propos
exploit
ofliposom
target
cell
re
may
enhanc
therapeut
efficaci
varieti
parasit
fungal
bacteri
macrophageassoci
diseas
includ
schistosomiasi
leishmaniasi
histoplasmosi
cryptococcosi
brucellosi
salmonellosi
viral
diseas
potenti
treatabl
liposomeencapsul
drug
includ
review
sever
group
virus
product
infect
cell
re
viru
replic
monocytesmacrophag
integr
factor
pathogenesi
certain
sever
system
viru
infect
macrophag
primordi
defens
cell
virtu
locat
throughout
bodi
capac
respond
chemotact
stimuli
often
accumul
earli
site
mani
viru
infect
moreov
activ
varieti
factor
macrophag
becom
select
cytostat
cytotox
virusinfect
cell
without
damag
normal
cell
would
like
propos
natur
target
liposom
mononuclear
phagocyt
exploit
examin
whether
select
deliveri
antivir
immunomodulatori
agent
could
benefici
treatment
viral
diseas
report
wish
discuss
potenti
use
liposom
treatment
viral
diseas
follow
perspect
target
liposomeencapsul
immunomodul
macrophag
order
render
cell
cytolyt
virusinfect
cell
b
target
liposomeencapsul
antivir
drug
immunomodul
macrophag
achiev
direct
suppress
viru
replic
within
cell
c
advantag
limit
futur
direct
approach
therapi
major
thrust
current
antivir
research
direct
toward
develop
drug
select
block
viru
replic
without
caus
toxic
effect
host
cell
strategi
led
develop
compound
amantadin
antiinfluenza
agent
inhibit
viru
uncoat
acyclovir
antiherp
agent
inhibit
herp
simplex
viru
hsv
specifi
dna
polymeras
howev
present
lack
control
treatment
overwhelm
major
virus
pathogen
man
anim
mandat
search
therapeut
mode
acut
viral
infect
produc
inflammatori
respons
characterist
perivascular
infiltr
mononuclear
cell
major
mononuclear
phagocyt
macrophag
import
compon
host
frontlin
defens
viru
infect
strateg
locat
portal
entri
virus
blood
viscer
organ
facilit
task
macrophag
accumul
site
primari
viru
infect
enhanc
releas
chemotact
stimuli
foci
viru
replic
viral
reinfect
interact
viruscod
protein
sensit
lymphocyt
postul
trigger
releas
solubl
mediat
ie
lymphokin
chemotact
macrophag
also
activ
macrophag
antivir
effect
activ
macrophag
acquir
capabl
discrimin
virusinfect
normal
cell
mechan
macrophag
select
virusinfect
uninfect
cell
unknown
although
virusinduc
chang
macromolecular
constitut
host
cell
plasma
membran
appear
play
major
role
fact
recent
studi
recombin
reovirus
suggest
recognit
site
reovirusinfect
target
cell
mous
periton
cell
viru
hemagglutinin
protein
collect
data
suggest
macrophag
import
factor
host
defens
viral
diseas
list
acut
viral
infect
select
cytostat
cytolyt
effect
macrophag
virusinfect
cell
demonstr
shown
tabl
addit
effect
macrophag
also
restrict
replic
sever
virus
infect
cell
cultur
tabl
enhanc
antivir
activ
macrophag
also
occur
subsequ
interact
nonspecif
bacteri
product
lymphokin
despit
signific
antivir
activ
vitro
attempt
immunomodul
prophylaxi
treatment
viral
infect
vivo
may
due
part
rapid
clearanc
lymphokin
macrophag
activ
circul
inabl
target
suffici
quantiti
immunomodul
macrophag
recent
studi
laboratori
demonstr
macrophag
human
peripher
blood
monocyt
activ
vitro
varieti
free
liposomeencapsul
substanc
lymphokin
contain
macrophageactiv
factor
maf
human
recombin
gamma
interferon
bacteri
lipopolysaccharid
muramyl
dipeptid
deriv
select
lyse
hsvinfect
cell
without
harm
uninfect
cell
calcul
intern
volum
liposom
indic
total
amount
liposomeencapsul
immunomodul
approxim
time
lower
volum
free
substanc
need
induc
macrophag
activ
cytolyt
state
sinc
compar
level
cytotox
virusinfect
cell
observ
free
liposomeencapsul
immun
modifi
result
demonstr
liposom
encapsul
significantli
augment
effici
macrophag
activ
control
experi
macrophag
incub
liposom
contain
cultur
media
suspend
dilut
maf
exhibit
activ
cytotox
state
thu
mechan
macrophag
activ
via
liposomeencapsul
immunomodul
simpli
due
alter
macrophag
function
liposom
requir
intern
immunomodulatori
substanc
result
close
agre
amplif
tumoricid
activ
macrophag
liposom
contain
immunomodul
sinc
intraven
administ
liposom
clear
macrophag
evalu
efficaci
treatment
murin
model
system
liposom
contain
macrophag
activ
significantli
protect
mice
lethal
infect
wherea
administr
free
unencapsul
immunomodul
produc
margin
effect
koff
wc
et
al
submit
public
data
indic
deliveri
macrophag
activ
cell
re
via
liposom
significantli
modul
outcom
acut
viral
infect
interact
virus
macrophag
cover
broad
spectrum
event
rang
phagocytosi
destruct
viru
particl
acut
persist
viru
infect
factor
influenc
outcom
virusmacrophag
interact
complex
includ
viru
type
presenc
absenc
virusspecif
antibodi
avail
viral
receptor
macrophag
genet
suscept
age
immunocompet
host
stage
differenti
macrophag
progress
unstimul
cytolyt
phenotyp
tabl
describ
group
virus
replic
demonstr
occur
within
macrophag
along
correspond
human
diseas
caus
virus
find
mean
confin
human
viral
infect
tabl
list
sever
sever
system
viral
diseas
domest
anim
viru
replic
also
known
occur
macrophag
econom
import
diseas
estim
billion
dollar
inabl
control
virus
vaccin
chemotherapi
signifi
need
examin
therapeut
approach
sinc
liposom
target
natur
monocyt
follow
intraven
administr
possibl
direct
antivir
drug
immunomodul
virus
replic
within
macrophag
therebi
modifi
viru
infect
recent
studi
kend
et
al
support
hypothesi
studi
rift
valley
fever
viru
rvfv
replic
liver
macrophag
central
nervou
system
cn
examin
murin
model
system
small
inocula
plaqueform
unit
caus
death
day
infect
due
liver
necrosi
cn
inflamm
intraven
inject
liposom
contain
lipophil
deriv
muramyl
dipeptid
mdp
brought
signific
therapeut
effect
measur
mean
surviv
time
percent
surviv
effect
observ
even
mice
treat
late
day
infect
intraven
administr
periarthr
synov
free
mdp
even
time
dose
administ
liposom
effect
find
suggest
activ
macrophag
liposom
contain
immunomodul
suppress
replic
virus
cell
therebi
inhibit
spread
infect
consequ
diminish
sever
diseas
principl
theoret
could
test
broad
spectrum
antivir
agent
interferon
ribavirin
fact
encapsul
activ
alpha
gamma
interferon
liposom
alreadi
success
accomplish
vitro
report
describ
potenti
use
liposom
vehicl
select
deliveri
antivir
agent
immunomodul
monocytesmacrophag
prophylaxi
therapi
viral
diseas
although
approach
logic
attract
field
infanc
expect
need
realist
advantag
limit
possibl
futur
direct
liposomemedi
antivir
therapeut
must
consid
liposom
provid
attract
vehicl
deliveri
drug
macrophag
liposom
concentr
phagocyt
cell
drug
concentr
cytoplasm
macrophag
manyfold
higher
nonphagocyt
cell
reason
total
dose
antivir
drug
administ
liposom
could
well
sever
log
less
use
drug
inject
free
unencapsul
form
reduc
dose
drug
coupl
select
drug
target
natur
bring
signific
reduct
system
even
local
drugassoci
toxic
liposom
also
provid
vehicl
deliveri
two
complementari
antivir
agent
target
cell
presenc
one
antivir
agent
desir
combin
ratio
site
viral
replic
situ
could
synergist
antivir
activ
encapsul
lymphokin
mdp
within
liposom
shown
induc
synergist
activ
oftumoricid
properti
alveolar
macrophag
similar
result
could
well
obtain
combin
chemotherapi
treatment
drugresist
viru
mutant
mean
lower
dose
drug
requir
antivir
efficaci
use
liposom
contain
immunomodul
treatment
viral
diseas
may
contraind
virus
reportedli
enhanc
replic
activ
macrophag
recent
vitro
studi
hotta
hotta
demonstr
dengu
virus
produc
significantli
greater
titer
viru
activ
macrophag
unstimul
cell
similarli
alphavirus
coronavirus
replic
greater
effici
macrophag
treat
varieti
stimul
agent
resid
macrophag
thu
viru
replic
macrophag
issu
import
analyz
abil
viru
question
replic
activ
macrophag
prior
examin
vivo
antivir
therapeut
efficaci
liposomeencapsul
immunopotenti
agent
tempor
associ
virusinfect
cell
activ
macrophag
kinet
cytotox
may
also
play
promin
role
therapeut
effect
relat
macrophag
mediat
lysi
virusinfect
cell
kill
cell
infect
cytolyt
viru
assembl
infecti
viru
would
abort
replic
cycl
even
lysi
cell
viru
assembl
would
probabl
result
reduct
viru
limit
viru
spread
howev
lysi
infect
cell
prior
virusinduc
lysi
could
enhanc
diseas
process
speed
cytolysi
infect
cell
concomit
viru
spread
thu
macrophagemedi
lysi
cell
infect
virus
rel
slow
replic
cycl
eg
cytomegaloviru
might
effect
lysi
cell
infect
faster
replic
cycl
eg
influenza
although
treatment
macrophageassoci
diseas
parasit
fungal
origin
liposomeencapsul
drug
receiv
much
attent
pauciti
inform
potenti
use
approach
treatment
viral
diseas
sever
import
area
research
need
examin
concern
approach
viral
therapeut
includ
determin
viru
group
suscept
treatment
vitro
vivo
liposomeencapsul
antiviralsimmunopotenti
agent
natur
phospholipid
constitut
liposom
produc
optim
therapeut
effect
dosag
schedul
combin
chemotherapi
studi
toxic
studi
addit
recent
find
demonstr
persist
slow
virus
caprin
arthriti
enceph
viru
replic
macrophag
modifi
intern
biochem
natur
macrophag
immunopotenti
agent
known
significantli
increas
lysosom
enzym
metabol
rate
macrophag
might
also
possibl
modul
chronic
infect
event
select
target
liposom
contain
antivir
immunopotenti
agent
phagocyt
cell
bodi
could
provid
import
new
approach
therapi
sever
debilit
viral
diseas
